TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Monitoring Everyday Life Motor Activity in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Various neuro-orthopedic diagnoses. Broad inclusion criteria are required to better generalize study results to the patient population of our center.~* Both walking or in wheelchair, but mobility independent from assisting people~* Cognitive ability to be able to follow simple verbal instructions.~* Signed informed consent from legal guardians and also from adolescents aged 15 years or older before study onset.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Inpatients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory multiple myeloma following 1 previous line of therapy and, is scheduled by the investigator to be treated with vincristine, adriamycin and dexamethasone standard therapy~* measurable secretory multiple myeloma based on defined criteria~* Karnofsky performance status of \>or = 60%~* fulfils defined laboratory requirements within 14 days before baseline~* if female, the patient is either postmenopausal or surgically sterilised or willing to use an acceptable method of birth control for defined period of time~* if male, the patient agrees to use an acceptable barrier method for contraception for a defined period of time.~Exclusion Criteria:~* More than one previous line of therapy for multiple myeloma~* use of bortezomib in the previous line of therapy and/or received bortezomib in a previous trial~* known allergy or hypersensitivity to bortezomib, boron or mannitol~* peripheral neuropathy or neuropathic pain of grade 2 or higher~* myocardial infarction within 6 months of enrollment or had New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VAD Treatment (Type: ACTIVE_COMPARATOR): vincristine in combination with adriamycin and dexamethasone
- PAD Treatment (Type: EXPERIMENTAL): bortezomib in combination with adriamycin and dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years and older~* Closed or open distal femur fracture (AO 33 A1-3, 33 C1-3) including distal femur fractures above a total knee arthroplasty~* Ability to walk independently prior to injury~* Eligible for treatment with ORIF of the distal femur with a large fragment locking plate (LISS, LCP)~* Willing and able to comply with post-operative protocol and return for follow-up.~* Ability to understand the content of the patient information / informed consent form and participate in the clinical investigation~* Signed informed consent~Exclusion Criteria:~* Additional ipsi- or contralateral lower extremity fracture~* Any kind of implant at the ipsilateral proximal femur~* Pre-existing malunion or nonunion of the ipsilateral lower extremity~* Segmental bone defect requiring bone grafting~* More than 4 weeks between injury and surgery~* Pathologic fracture due to a disease other than osteoporosis (eg, tumor, metastasis)~* Polytrauma~* Active malignancy~* Any not medically managed severe systemic disease~* Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment~* Pregnancy or women planning to conceive within the study period~* Prisoner~* Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- DLS 5.0 (Dynamic Locking Screws) (Type: ACTIVE_COMPARATOR): ORIF with DLS 5.0 (Dynamic Locking Screws)
- SLS (Standard locking screw) (Type: ACTIVE_COMPARATOR): ORIF with SLS (Standard locking screw)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must be ≥ 18 years old at the time of signing the ICF.~* The patient must have a histologically proven adenocarcinoma of the colon or rectum.~* The patient must have liver metastases non treatable with curative intent by surgical resection or local ablation at the time of registration.~* The patient must have measurable hepatic metastases defined by RECIST version 1.1 for solid tumors.~* The patient must have received one prior chemotherapy line for metastatic disease and have developed resistance or intolerance to this treatment.~* The patient must have an ECOG performance status 0 or 1.~* The patient must have the bone marrow reserve, hepatic and renal functions~Exclusion Criteria:~* Patients who are presenting evidence of ascites, cirrhosis, portal hypertension, main portal venous tumor involvement or thrombosis as determined by clinical or radiologic assessment.~* Patients who are planned to receive or concurrently receiving any non-cancer-directed investigational agent, or have received a non-cancer directed investigational agent within 3 weeks before the planned day for the first NKR-2 administration.~* Patients who are scheduled to receive concurrent growth factor (except erythropoietin), systemic steroid, other immunosuppressive therapy or cytotoxic agents (systemic or localized) other than the treatment authorized per protocol.~* Patients who underwent major surgery within 4 weeks before the planned day for the first NKR-2 administration.~* Patients who have received a live vaccine ≤ 6 weeks prior to the planned day for the first NKR-2 administration.~* Patients with a family history of congenital or hereditary immunodeficiency.~* Patients with history of any autoimmune disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose-level 1 (Type: EXPERIMENTAL): The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
- Dose-level 2 (Type: EXPERIMENTAL): The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
- Dose-level 3 (Type: EXPERIMENTAL): The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: C1q/TNF-related Proteins in Coronary Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 20\<age\<80~* History of stable angina, unstable angina, or acute myocardial infarction~Exclusion Criteria:~* a history of diabetes~* stage 2 hypertension~* malignancy~* severe renal or hepatic disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Patients with CAD (Type: None): Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Indole-3-Carbinol Effects on Estrogen Metabolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* woman aged from 30 - 50 years~* regular menstrual cycle~Exclusion Criteria:~* taking hormone replacement or hormonal contraception~* thyroid disorder~* uncontrolled asthma~* BMI under 18.5~* allergy to cruciferous vegetables

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Indole-3-carbinol (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MRI Evaluation of the Breast Areolar Margin and Paryenchyma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have one of the following indications for MRI study of the breast - screening for high risk without evidence of disease, have existing breast cancer with need for evaluation of extent of disease or to rule out additional occult cancer, or to have an equivocal mammogram or ultrasound requiring additional information from MRI.~* No prior breast surgery including prior excisional biopsies for disease performed with surgical technique, breast augmentation, reduction mammoplasty or breast lift with or without implants.~* Capable of fitting into the MRI machine.~* Permission to contact and consent the patient to participate from the investigator(s)~* Provide written informed consent and Authorization for Use/Disclosure of PHI~Exclusion Criteria:~* Have a contraindication to MRI study.~* Prior breast surgery - this includes: prior excisional biopsies for disease performed with surgical technique, breast augmentation, reduction mammoplasty or breast lift with or without implants \[Patients may have undergone prior percutaneous (needle) biopsy or fine needle aspiration\]~* Inability to fit into the MRI machine.~* Psychological factors that may interfere with successful completion of the study~* Refusal to provide written informed consent and/or Authorization for Use/Disclosure of PHI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI (Type: OTHER): All patients on study will undergo an MRI of the breast(s).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must provide informed consent before any study specific evaluation is performed.~* Subject is male or female aged 18 to 70 years, inclusive.~* Subject has a grade 1 (mild functional impairment) or grade 2 (moderate functional impairment) ankle strain or sprain that occurred within 48 hours before the Screening visit.~* Subject has pain intensity upon monopodal weight bearing of 5 to 8, inclusive, measured by an 11 point nominal rating scale (NRS), plus pain intensity score at rest that is less than upon monopodal weight bearing.~Exclusion Criteria:~* Subject has a grade 3 (severe functional impairment) strain or sprain, bilateral strain or sprain, or concomitant fracture or wound at the site of the strain or sprain.~* Subject has had an ankle strain or sprain to the same foot within 6 months before the Screening visit.~* Subject has received topical analgesic medication within 24 hours before the Screening visit.~* Subject has applied ice or compression to the injured area within 2 hours before the Screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo patch: 0% indomethacin
- K-103-IP (Type: EXPERIMENTAL): K-103-IP: 0.5% indomethacin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a elevated risk, surgical stage II, stage IC, grade 2 or 3 adenocarcinoma of the endometrium.~* Patients must have undergone, a total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and a pelvic and para-aortic lymphadenectomy.~* Patients must have adequate organ function defined as:~  1. Platelets \>/= 100,000/µ~ 2. Granulocytes (ANC)\>/= 1,500/µl~ 3. Creatinine\</= 1.6 mg/dl~ 4. SGOT (AST) \</= 3x upper limits of normal~ 5. Bilirubin within institutional normal limits~* Patients must have adequate performance status (ECOG performance status 0-2 or Karnofsky Performance Status \>40)~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients with history of other malignancies within 5 years (except non- melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.~* Patients with high-risk histologic subtypes of endometrial cancer such as papillary serous or clear cell histology are ineligible.~* Patients with histologic evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.~* Patients who have received past pelvic radiotherapy are ineligible.~* Patients receiving any other investigational agents are ineligible.~* Patients with known hypersensitivity to paclitaxel and/or carboplatin are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study for a Botulinum Toxin Type A Injection to Treat Habitual Snoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects aged 18-70~* Subjects suffering from snoring for at least 3 months prior to the study start and seeking for help to treat snoring~* Subjects with a peak Snoring Index \[SI\] ≥ 15/ hour of sleep \[h\] at baseline visit~* Subjects with a bed partner for at least three months prior to study start.~* Subjects who understand the nature of the study and provide written Informed Consent at screening visit.~* Subjects who understand the study procedures as well as possess the ability and willingness to abide by all procedures during the course of the study~Exclusion Criteria:~* Obese subjects (Body Mass Index ≥ 30)~* Subjects with severe obstructive sleep apnea syndrome~* Subjects with Apnea-Hypopnea Index ≥ 10 /hour of sleep and/ or Respiratory Disturbance Index ≥ 25 / hour of sleep at the baseline visit~* Subjects who have undergone any Botulinum neurotoxin treatment in the history~* Subjects with generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert-Eaton syndrome)~* Acute infections of the pharynx

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U (Type: EXPERIMENTAL): IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have confirmation of AML by WHO criteria, except for APL (M3)~2. Subject must be ≥ 65 years of old and be ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidity or other factors~3. Subject must have received no prior treatment for AML with the exception of hydroxyurea~4. ECOG performance status of 0-1. For dose-expansion stage, ECOG PS of 2 will also be eligible~Exclusion Criteria:~1. Subject has received treatment of hypomethylating agent and/or chemo therapeutic agent for MDS or MPN~2. Subject has known active CNS involvement or extramedullary sarcoma from AML~3. Subject has favorable risk cytogenetics as categorized by the NCCN Guidelines Version 1, 2018 for Acute Myeloid Leukemia, such as inv(16) or t(16;16) or t(8;21) or t(15;17)~4. Subject has a white blood cell count \> 25 × 109/L (Hydroxyurea is permitted to meet this criterion)~5. Subject with serum amylase or lipase \> the ULN~6. Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load.~7. Subject who don't have enough liver or renal function~8. Subject with New York Heart Association (NYHA) Class III or greater congestive heart failure~9. Subject received herbal therapy ≤ 1 week prior to initiation of study treatment~10. Subject received prior treatment with any SYK inhibitors (Fostamatinib) or FLT3 inhibitor (Quizartinib) or multi-target inhibitor with SYK or FLT3 inhibition activity (Midostaurin)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HMPL-523 & Azacitidine (Type: EXPERIMENTAL): HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Lymph Node Procedure in Ipsilateral Invasive Breast Cancer Relapse

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥ 18 years old~2. Invasive recurrence (ductal, lobular, other), homolateral breast carcinoma~3. Size of the tumor with ultrasound ≤ 5cm~4. Initial conservative surgery~5. Patient who has already received SLND for her initial cancer, regardless of the SLND result~6. Procedure for the detection of lymph node sentinel by isotopic method +/- colorimetric~7. Minimum delay of one year between the end of radiotherapy for initial breast carcinoma and the treatment / management of ipsilateral recurrence~8. Pregnancy test (urinary or blood) negative for premenopausal patients~9. Information of the patient and obtaining written consent, signed by the patient and the investigator~Exclusion Criteria:~1. Non-invasive recurrence~2. History of ipsilateral axillary dissection~3. History of ipsilateral mastectomy~4. Patient pN + before surgery~5. Metastasis~6. Allergy known to 2 detection products (Blue and radioactive tracer)~7. Pregnant or lactating woman~8. Patient protected or under guardianship or unable to give consent~9. Impossibility of submitting to the medical examination for geographical, social or psychological reasons

- Gender: None
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sentinel LN in breast cancer recurrence (Type: EXPERIMENTAL): Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues